Observes Epcoritamab Use in Adults With Two Types of Lymphoma
Studies how the drug epcoritamab works in adults with lymphoma in everyday care.
Plain-language title generated from the registry record
Registry title: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Key facts
- Where
- Edmonton, Greater Sudbury, Kingston, Moncton, and St. John's, CanadaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diffuse large B-cell lymphoma or follicular lymphoma who are scheduled to get epcoritamab after two or more earlier treatments.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diffuse large B-cell lymphoma or follicular lymphoma that needs treatment after two or more prior lines of therapy (3L+).
- Earlier treatment
- Two or more prior lines of therapy. The doctor decided on epcoritamab before and independently of this study.
Main reasons for not taking part
- Any condition listed as a contraindication in the approved local epcoritamab label
- Taking part in another interventional clinical trial at the same time
Read by machine on 12 November 2026.
Where in Canada
- Cross Cancer Institute /ID# 271504Edmonton, CanadaContact: Rebekah TaylorTaking people
- Health Sciences North /ID# 274738Greater Sudbury, CanadaContact: Rebekah TaylorTaking people
- Kingston General Hospital /ID# 272061Kingston, CanadaContact: Rebekah TaylorTaking people
- The Moncton Hospital /ID# 277230Moncton, CanadaContact: Rebekah TaylorTaking people
- Eastern Health - General Hospital /ID# 272062St. John's, CanadaContact: Rebekah TaylorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT06830759
- Record updated
- 17 February 2026
- Original description
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.Read full original descriptionShow less
EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.
Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.
Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL); Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country; The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
Exclusion: Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study; Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.